转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA-617治疗期间[18F]FDG PET/CT再分期的预后价值
视觉进展和MTV增加≥20%均与更短的无进展生存期和更低的PSA-50应答相关,视觉进展与总生存期无显著差异。
要点
- interim [18F]FDG PET视觉进展与更短PFS和更低PSA-50应答相关
- MTV增加≥20%与更短PFS和更低PSA-50应答相关
- 视觉进展和MTV增加与OS差异均未达统计学显著
核心结论
- interim [18F]FDG PET的视觉和定量变化对接受[177Lu]Lu-PSMA治疗患者的PFS有预后价值,并与PSA应答相关。
主要发现
- 18例(53%)出现视觉进展,中位PFS为1.2个月(95%CI 0.7-2.0),无视觉进展者为5.2个月(95%CI 3.6-7.0),P=0.0005。
- 视觉进展者PSA-50应答率为28%,无视觉进展者为75%,P=0.015。
- 视觉进展者中位OS为10.3个月(95%CI 6.1-17.1),无视觉进展者为16.4个月(95%CI 10.5-21.4),P=0.090。
- 11例(32%)MTV增加≥20%,其中位PFS为0.7个月(95%CI 0.6-1.4),其余患者为4.9个月(95%CI 2.2-6.6),P<0.0001。
- MTV增加≥20%者PSA-50应答率为9.1%,其余患者为70%,P=0.002;中位OS分别为10.8个月(95%CI 2.1-17.1)和16.4个月(95%CI 10.3-20.1),P=0.069。
临床怎么用
- interim [18F]FDG PET的视觉进展和MTV增加≥20%可辅助识别PFS较短、PSA应答率较低的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We analyzed the prognostic value of an interim [18F]FDG PET/CT performed after cycle 3 of [177Lu]Lu-PSMA-617 ([177Lu]Lu-PSMA) for patients undergoing therapy for metastatic castration-resistant prostate cancer (mCRPC). Methods: We retrospectively reviewed the data of patients with mCRPC in the ProsTIC Registry (NCT04769817) receiving [177Lu]Lu-PSMA who underwent [18F]FDG PET/CT at both baseline and after cycle 3. Parameters included visual response assessment (progression vs. no progression) and metabolic tumor volume (MTV) (≥20% increase vs. <20% increase or any decrease). Outcomes were measured against reductions of 50% or greater in prostate-specific antigen (PSA) levels (PSA-50) by Fisher exact test and time-to-event outcomes. PSA progression-free survival (PFS) and overall survival (OS) were defined relative to cycle 3, using Kaplan-Meier estimation. Results: Thirty-four patients (median age, 72 y; interquartile range, 66-77 y) were eligible for study inclusion. Their median PSA was 58 ng/mL (interquartile range, 17-176 ng/mL) before treatment. All patients had prior treatment with androgen receptor pathway inhibitors, and 33 had received at least 1 line of chemotherapy. Visual progression on interim [18F]FDG PET was observed in 18 patients (53%) and was associated with shorter median PFS after cycle 3 (1.2 mo; 95% CI, 0.7-2.0) compared with those patients without visual progression (5.2 mo; 95% CI, 3.6-7.0) (P = 0.0005) and lower achievement of PSA-50 (28% vs. 75%, P = 0.015). Median OS did not significantly differ between those with and without visual progression (10.3 mo; 95% CI, 6.1-17.1 mo vs. 16.4 mo; 95% CI, 10.5-21.4 mo, respectively) (P = 0.090). An increase of at least 20% in MTV was observed in 11 patients (32%) who, when compared with those whose MTV increased or decreased by less than 20%, had a shorter median PFS (0.7 mo; 95% CI, 0.6-1.4 mo vs. 4.9 mo; 95% CI, 2.2-6.6 mo; P < 0.0001) and OS (10.8 mo; 95% CI, 2.1-17.1 mo vs. 16.4 mo; 95% CI, 10.3-20.1 mo; P = 0.069) and lower PSA-50 response (9.1% vs. 70%, P = 0.002). Conclusion: Visual and quantified changes on interim [18F]FDG PET appeared prognostic for PFS in patients undergoing [177Lu]Lu-PSMA therapy and correlated with PSA response. Further studies are needed to determine whether [18F]FDG PET could serve as an independent biomarker to guide treatment intensification or de-escalation, including treatment pauses.
引用
- Kashyap R, Buteau JP, Papa N, et al. Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy. J Nucl Med. 2026. PMID: 42350033. doi:10.2967/jnumed.126.272531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。